{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:34:25Z","timestamp":1761237265057},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1053\/j.seminoncol.2004.03.023","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T13:58:14Z","timestamp":1131026294000},"page":"20-24","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S5","title":["Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: Preliminary results from a phase II trial"],"prefix":"10.1053","volume":"31","author":[{"given":"Amadeu","family":"Pelegr\u0131\u0301","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 I","family":"Mayordomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Flori\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angels","family":"Arcusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Mart\u0131\u0301n-Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L","family":"Bayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Virizuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2004.03.023_BIB1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","article-title":"Cancer Statistics, 2002","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.1996.14.8.2197","article-title":"Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer","volume":"14","author":"Greenberg","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB3","series-title":"Breast Cancer Management","first-page":"63","article-title":"Taxanes","author":"Nabholtz","year":"2000"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB4","series-title":"Adjuvant taxanes","first-page":"58","author":"Vogel","year":"2003"},{"issue":"suppl 3","key":"10.1053\/j.seminoncol.2004.03.023_BIB5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/sonc.2003.37268","article-title":"Monotherapy options in the management of metastatic breast cancer","volume":"30","author":"Seidman","year":"2003","journal-title":"Semin Oncol"},{"issue":"suppl 11","key":"10.1053\/j.seminoncol.2004.03.023_BIB6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/sonc.2002.34055","article-title":"Gemcitabine and targeted therapy in metastatic breast cancer","volume":"29","author":"Qu","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/07357900009012188","article-title":"Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer","volume":"18","author":"Fountzilas","year":"2000","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1008315723253","article-title":"Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine","volume":"10","author":"Mavroudis","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB9","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1023\/A:1012247311419","article-title":"Monthly docetaxel and weekly gemcitabine in metastatic breast cancer","volume":"12","author":"Laufman","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB10","first-page":"52b","article-title":"Salvage chemotherapy with docetaxel (TXT) and gemcitabine (GEM) in metastatic breast cancer (MBC)","volume":"20","author":"Brandi","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB11","first-page":"119a","article-title":"Phase I trial of sequential docetaxel and gemcitabine","volume":"20","author":"Ishmael","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB12","first-page":"49b","article-title":"Evidence for in vivo synergism between docetaxel (DOC) and gemcitabine (GEM) in patients with metastatic breast cancer 9MBC)","volume":"20","author":"Alexopoulos","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB13","first-page":"226a","article-title":"Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules","volume":"18","author":"Rigas","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00280-002-0548-x","article-title":"Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer","volume":"51","author":"Vassinomanolakis","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB15","first-page":"3575","article-title":"First-line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study","volume":"21","author":"Pectasides","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB16","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer","volume":"20","author":"O\u2019Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB17","first-page":"42","article-title":"Final results of a phase II clinical trial of weekly docetaxel (T) in combination with capecitabine (X) in anthracycline pre-treated metastatic breast cancer (MBC)","volume":"22","author":"Mackey","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00000421-200304000-00005","article-title":"Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer","volume":"26","author":"Gomez-Bernal","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1023\/A:1011691307995","article-title":"Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines","volume":"12","author":"Marti","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB20","first-page":"1051","article-title":"Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor","volume":"8","author":"Kornek","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.03.023_BIB21","first-page":"7","article-title":"Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracyclines pre-treated metastatic breast cancer (MBC)","volume":"22","author":"O\u2019Shaughnessy","year":"2003","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404001277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404001277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T17:03:18Z","timestamp":1586538198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775404001277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":21,"alternative-id":["S0093775404001277"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.03.023","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}